HH
CRSP icon

Hilltop Holdings’s CRISPR Therapeutics CRSP Stock Holding History

Hilltop Holdings’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,322
Closed -$541K – 692
2025
Q4 		$541K Buy
+10,322
New +$618K 0.03% 521
2018
Q2 		– Sell
-20,109
Closed -$919K – 420
2018
Q1 		$919K Buy
+20,109
New +$830K 0.16% 153

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Hilltop Holdings's CRSP Position: Q1 2026 in Review

Hilltop Holdings sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 10,322 shares — an estimated $541K sold.

Hilltop Holdings first reported a position in CRSP in Q1 2018 and held it in 2 quarters. The position peaked at $919K in Q1 2018. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Hilltop Holdings reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hilltop Holdings sold 10,322 CRISPR Therapeutics shares in Q1 2026, an estimated $541K.
  • Hilltop Holdings first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 2 quarters.
  • Hilltop Holdings's CRISPR Therapeutics position peaked at $919K in Q1 2018.
  • 492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Hilltop Holdings's 13F filing for Q1 2026, filed 14 May 2026.